{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:39:16Z","timestamp":1760146756732,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Radiotherapy represents the only treatment option for patients with inoperable endometrial cancer (EC). The aim of our study was to evaluate the efficacy and safety of brachytherapy (BT) in this selected patient population. Methods: Between 1990 and 2019, 18 patients with inoperable EC in stage FIGO I\u2013IV were treated with intracavitary brachytherapy using the \u201cHeyman Packing technique\u201d. BT was performed either as sole PDR- or HDR-brachytherapy with a median cumulative dose up to 60.0 Gy (67.9 Gy EQD2 \u03b1\/\u03b2 = 3Gy) and 34.0 Gy (75.6 Gy EQD2 \u03b1\/\u03b2 = 3Gy), respectively. Results: The median follow-up was 46 months (6\u2013219). The mean age was 71 years. The 5-year cumulative local recurrence rate (CLRR) for the whole cohort was 27.3%. The 5-year overall survival (OS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were 51%, 79%, and 69%. The 5-year DFS for low-, intermediate-, and high-risk EC was 89%, 50%, and 44% (p = 0.51). No significant difference in DFS was observed in patients over 70 (p = 0.526). No late side effects of grade &gt; 1 were documented. Conclusions: Brachytherapy for inoperable EC is a safe and effective treatment option, offering good local control and OS with minimal toxicity. Moreover, brachytherapy effectively controls hemoglobin-relevant bleeding. Therefore, BT should be considered a viable alternative to non-curative treatment strategies in gynecological multidisciplinary conferences.<\/jats:p>","DOI":"10.3390\/jpm14121138","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:18:32Z","timestamp":1733217512000},"page":"1138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Brachytherapy in Inoperable Endometrial Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Ricarda","family":"Merten","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vratislav","family":"Strnad","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lotter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kreppner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0353-6283","authenticated-orcid":false,"given":"Philipp","family":"Schubert","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Karius","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Universit\u00e4tsstrasse 27, 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (2005). ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: Management of endometrial cancer. Obs. Gynecol., 106, 413\u2013425.","DOI":"10.1097\/00006250-200508000-00050"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/dju402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/modpathol.2014.143","article-title":"Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations","volume":"28","author":"Hussein","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s13193-022-01523-9","article-title":"Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation","volume":"13","author":"Tresa","year":"2022","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_7","first-page":"4667","article-title":"Prognostic Significance of p53 Overexpression in Endometrial Cancer","volume":"54","author":"Ito","year":"1994","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1055\/a-2066-2051","article-title":"Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032\/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures","volume":"83","author":"Emons","year":"2023","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00066-020-01735-4","article-title":"The PORTEC-3 trial for high-risk endometrial cancer: Impact of molecular classification on prognosis and benefit from adjuvant therapy","volume":"197","author":"Marnitz","year":"2021","journal-title":"Strahlenther. Onkol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Safaei, M., Sundararajan, E.A., Driss, M., Boulila, W., and Shapi\u2019i, A. (2021). A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput. Biol. Med., 136.","DOI":"10.1016\/j.compbiomed.2021.104754"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/bjs.10899","article-title":"Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy","volume":"105","author":"Fleming","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1055-9965.EPI-23-1444","article-title":"Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)","volume":"33","author":"Habeshian","year":"2024","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1055-9965.EPI-14-0923","article-title":"Metabolic syndrome and risk of endometrial cancer in the united states: A study in the SEER-medicare linked database","volume":"24","author":"Trabert","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2016.07.005","article-title":"Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma","volume":"65","author":"Christiaens","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Arians, N., Oelmann-Avendano, J.T., Schmitt, D., Meixner, E., Wark, A., Hoerner-Rieber, J., El Shafie, R.A., Lang, K., Wallwiener, M., and Debus, J. (2020). Evaluation of Uterine Brachytherapy as Primary Treatment Option for Elderly Patients with Medically Inoperable Endometrial Cancer-A Single-Center Experience and Review of the Literature. Cancers, 12.","DOI":"10.3390\/cancers12082301"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2020.05.032","article-title":"Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients","volume":"158","author":"Espenel","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brachy.2020.01.003","article-title":"Upfront radiotherapy with brachytherapy for medically inoperable and unresectable patients with high-risk endometrial cancer","volume":"19","author":"Gannavarapu","year":"2020","journal-title":"Brachytherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.brachy.2015.06.002","article-title":"Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer","volume":"14","author":"Schwarz","year":"2015","journal-title":"Brachytherapy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.brachy.2019.05.003","article-title":"Vaginal brachytherapy alone for patients with Stage II endometrial cancer with inner half cervical stromal invasion","volume":"18","author":"Barnes","year":"2019","journal-title":"Brachytherapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00066-024-02207-9","article-title":"Transrectal ultrasound for intraoperative interstitial needle guidance in cervical cancer brachytherapy","volume":"200","author":"Knoth","year":"2024","journal-title":"Strahlenther. Onkol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/ijgc-2023-004695","article-title":"ESTRO\/ESGO\/SIOPe Guidelines for the management of patients with vaginal cancer","volume":"33","author":"Calaminus","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_24","unstructured":"Strnad, V., Niehoff, P., L\u00f6ssl, K., and Kirisits, C. (2023). Practical Handbook of Brachytherapy, UNI-MED. [2nd ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0167-8140(93)90267-C","article-title":"Application of the ICRU Report 38 reference volume concept to the radiotherapeutic management of recurrent endometrial and cervical carcinoma","volume":"26","author":"Bellotti","year":"1993","journal-title":"Radiother. Oncol."},{"key":"ref_26","first-page":"48","article-title":"ICRU report 89: Prescribing, recording, and reporting brachytherapy for cancer of the cervix","volume":"42","author":"Swamidas","year":"2017","journal-title":"J. Med. Phys."},{"key":"ref_27","unstructured":"Baltas, D., Kneschaurek, P., and Krieger, H. (1999). Dosisspezifikation in der HDR-Brachytherapie. DGMP Report No. 14, Leitlinien in der Radioonkologie P3, Deutsche Gesellschaft f\u00fcr Medizinische Physik."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1118\/1.597458","article-title":"Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine","volume":"22","author":"Nath","year":"1995","journal-title":"Med. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","article-title":"Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology","volume":"78","author":"Potter","year":"2006","journal-title":"Radiother. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1088\/0031-9155\/51\/16\/012","article-title":"Halftime for repair of sublethal damage in normal bladder and rectum: An analysis of clinical data from cervix brachytherapy","volume":"51","author":"Guerrero","year":"2006","journal-title":"Phys. Med. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.radonc.2012.07.003","article-title":"Long term results of a prospective dose escalation phase-II trial: Interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer","volume":"104","author":"Lettmaier","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0360-3016(95)00057-6","article-title":"RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system","volume":"31","author":"Rubin","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","article-title":"Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem","volume":"4","author":"Williams","year":"2015","journal-title":"Curr. Obes. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Collaboration NCDRF (2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet, 387, 1377\u20131396.","DOI":"10.1016\/S0140-6736(16)30054-X"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ijgc-2020-001573","article-title":"Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma","volume":"30","author":"Mueller","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/AOG.0b013e3181f39849","article-title":"Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics\u2019 Staging System for Uterine Corpus Cancer","volume":"116","author":"Lewin","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2022.11.012","article-title":"Recurrence and survival in endometrioid endometrial cancer\u2014A population-based cohort study","volume":"168","author":"Adok","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.5114\/aoms.2010.19305","article-title":"Long-term survival of endometrioid endometrial cancer patients","volume":"6","author":"Gottwald","year":"2010","journal-title":"Arch. Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00066-023-02061-1","article-title":"Non-endometrioid endometrial cancer: Analysis of recurrence pattern and identification of prognostic and treatment factors affecting recurrence and survival","volume":"199","author":"Lee","year":"2023","journal-title":"Strahlenther. Onkol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00066-020-01632-w","article-title":"The brave new world of endometrial cancer: Future implications for adjuvant treatment decisions","volume":"196","author":"Marnitz","year":"2020","journal-title":"Strahlenther. Onkol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00432-024-05772-9","article-title":"Treatment of endometrial cancer from 2000 to 2020 in Germany: A retrospective population based cohort study","volume":"150","author":"Papathemelis","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"Powell","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12094-021-02680-z","article-title":"Exclusive 3D-brachytherapy as a good option for stage-I inoperable endometrial cancer: A retrospective analysis in the gynaecological cancer GEC-ESTRO Working Group","volume":"24","author":"Rovirosa","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1006\/gyno.1995.9960","article-title":"High-dose-rate brachytherapy as the primary treatment of medically inoperable stage I-II endometrial carcinoma","volume":"59","author":"Nguyen","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0360-3016(96)00486-5","article-title":"Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: Results of 12 years of experience with 280 patients","volume":"37","author":"Knocke","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.brachy.2008.11.006","article-title":"The management of inoperable Stage I endometrial cancer using intracavitary brachytherapy alone: A 20-year institutional review","volume":"8","author":"Shenfield","year":"2009","journal-title":"Brachytherapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5114\/jcb.2017.67454","article-title":"Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer","volume":"9","author":"Draghini","year":"2017","journal-title":"J. Contemp. Brachyther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2017.09.006","article-title":"Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma","volume":"147","author":"Gebhardt","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: Improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20140018","DOI":"10.1259\/bjr.20140018","article-title":"Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer","volume":"87","author":"Dankulchai","year":"2014","journal-title":"Br. J. Radiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00066-023-02108-3","article-title":"Survey on brachytherapy training among radiation oncology residents in the German-speaking regions of Europe","volume":"199","author":"Knoth","year":"2023","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00066-023-02058-w","article-title":"Development, implementation, and results of a simulation-based hands-on brachytherapy workshop for medical students","volume":"199","author":"Drozdz","year":"2023","journal-title":"Strahlenther. Und Onkol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/12\/1138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:45:51Z","timestamp":1760114751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/12\/1138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jpm14121138"],"URL":"https:\/\/doi.org\/10.3390\/jpm14121138","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}